Anti-human complement c5 antibody and fusion protein thereof
AssigneeLongbio Pharma (Suzhou) Co., Ltd.
InventorsHaili MA, Heng LIU
Life of this patent
Estimating the term…
Abstract
The present invention relates to an antibody that specifically binds to complement C5, and a fusion protein thereof. The present invention also relates to a polynucleotide encoding the antibody or the fusion protein, an expression vector, and a host cell, and a pharmaceutical composition thereof, and a method and use for treating C5 protein-related diseases.
Claims54
An anti-C5 antibody or antigen-binding fragment thereof comprising three complementarity determining regions (CDRs) of a heavy chain variable region (VH), HCDR1, HCDR2, and HCDR3, and three CDRs of a light chain variable region (VL), LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, and HCDR3 are the three CDRs contained in the VH as set forth in SEQ ID NO:
- 39;
- and the LCDR1, LCDR2, and LCDR3 are the three CDRs contained in the VL as set forth in SEQ ID NO:
- 45.
An anti-C5 antibody or antigen-binding fragment thereof comprising:
- HCDR1 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO:
- 40,
- HCDR2 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO:
- 41,
- HCDR3 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO:
- 42,
- LCDR1 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO:
- 46,
- LCDR2 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO:
- 47, and
- LCDR3 comprising or consisting of the amino acid sequence as set forth in SEQ ID NO:
- 48.
Dependencies are inferred from the claim text.